Page 66 - MemoriaEHD-Eng

RESEARCH GROUPS

ó

ó
í

í

é

PROGRAMME:
Cholestasis and Metabolic G0081

Disorders

Group Members
Lead Researcher

STAFF MEMBERS
Castell Ripoll, José V.

Benet Gimenez, Marta

Contact:
ASSOCIATED MEMBERS

Hospital Universitario de La Fe. Bort Mart, Bernardo Roque
Donato Mart, Ma Teresa
Avda. Campanar, 21. Madrid.
E.mail: [email protected] · Website: http://www.iislafe.es/hepatologia.aspx
Gmez-Lechn Moliner, Ma Jos
Jover Atienza, Ramiro

Main lines of research

• Metabolism and hepatotoxicity of drugs: the objective is to design and va-

lidate new strategies for a more effective and safer drug development by

studying, in hepatic cellular models, the metabolism of new drugs, drug-
drug interactions and the molecular mechanisms of hepatotoxicity.

• Direct and indirect reprogramming of fibroblasts to hepatocytes/hepato-

blasts (iHEP): the objective is to develop a human liver cell model through

direct and indirect conversion of fibroblasts to iHEP. Direct conversion
takes place without prior reprogramming to iPS, while indirect conversion

involves first reprogramming fibroblasts to iPS cells and then their subse-
13
quent differentiation to iHEP.
20
T
• Pathogenesis of nonalcoholic fatty liver disease - transcriptional mecha- R
nisms involved: the objective is to discover new transcriptional mecha- PO
E
nisms involved in the development and progression of nonalcoholic fatty L R
A
liver disease (NAFLD) and to investigate the toxicogenomics of steatotic NU
drugs and their mechanisms. Moreover, we are searching for specific bio- N
A
markers able to differentiate between metabolic and drug-induced stea- /
HD
tosis.
E
ER
• Metabonomics liver and chemometrics: the objective is to correlate the IB
serum metabonome of patients who had undergone hepatocyte cell trans- C

66
plantation with their clinical outcome, and find changes in the level of